Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
XORTX Therapeutics Inc ( (TSE:XRTX) ) has issued an update.
XORTX Therapeutics Inc. announced a change of auditor, appointing Davidson & Company LLP as the new auditor effective January 16, 2025, following the resignation of Smythe LLP. This change has been reviewed by the audit committee and board of directors and filed on SEDAR+. There were no reservations or reportable events in the audit reports by the former auditor. The change is part of routine corporate governance and is not expected to impact the company’s operations or stakeholder relationships.
More about XORTX Therapeutics Inc
XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout. The company has three clinically advanced products: XRx-008 for ADPKD, XRx-026 for allopurinol intolerant gout, and XRx-101 for acute kidney and organ injury related to COVID-19. Additionally, XRx-225 is in the pre-clinical stage for Type 2 Diabetic Nephropathy. XORTX aims to improve the quality of life for patients with kidney disease and gout by targeting purine metabolism and xanthine oxidase to reduce uric acid production.
YTD Price Performance: -7.23%
Average Trading Volume: 3,790
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: C$5.36M
Learn more about XRTX stock on TipRanks’ Stock Analysis page.
